Cytek Biosciences (CTKB) Shares Outstanding (Diluted Average) (2020 - 2025)

Cytek Biosciences has reported Shares Outstanding (Diluted Average) for 6 years, with the latest figure at $126.9 million in Q2 2025.

• For the quarter ending Q2 2025, Shares Outstanding (Diluted Average) fell 3.24% year-over-year to $126.9 million; the trailing twelve-month figure through Jun 2025 stood at $126.9 million (down 3.24% YoY), and the FY2023 full-year result was $135.3 million, down 2.37% from the prior year.
• Shares Outstanding (Diluted Average) for Q2 2025 stood at $126.9 million, down from $132.8 million in the prior quarter.
• The five-year high for Shares Outstanding (Diluted Average) was $138.6 million in Q4 2022, with the low at $35.9 million in Q2 2021.
• Historically, Shares Outstanding (Diluted Average) has averaged $121.2 million across 5 years, with a median of $133.6 million in 2022.
• Annual changes were most pronounced in 2022 — Shares Outstanding (Diluted Average) soared 69.93% — and 2024, when it retreated 3.49%.
• Cytek Biosciences' Shares Outstanding (Diluted Average) stood at $81.5 million in 2021, then surged by 69.93% to $138.6 million in 2022, then dropped by 2.37% to $135.3 million in 2023, then slipped by 1.85% to $132.8 million in 2024, then fell by 4.41% to $126.9 million in 2025.
• The last three Shares Outstanding (Diluted Average) figures came in at $126.9 million (Q2 2025), $132.8 million (Q3 2024), and $131.2 million (Q2 2024), per Business Quant data.